Accendra Health Inc (OMI) FinancialsOMIAccendra Health Inc

Accendra Health Inc (OMI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diabetes, accounting for 28.0% of total sales, equivalent to $191.06M. Other significant revenue streams include Sleep therapy and Home respiratory therapy. Understanding this composition is critical for investors evaluating how OMI navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Accendra Health Inc maintains a gross margin of 42.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.14%, while the net margin is -0.80%. These profitability ratios, combined with a Return on Equity (ROE) of -196.39%, provide a clear picture of how effectively OMI converts its operational activities into shareholder value.

In the context of the broader market, OMI competes directly with industry leaders such as CATX and CRDF. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, OMI's gross margin of 42.02% stands against CATX's 100.00% and CRDF's 100.00%. Such benchmarking helps identify whether Accendra Health Inc is trading at a premium or discount relative to its financial performance.